Attached files
| file | filename |
|---|---|
| EX-32 - EX-32 - Celldex Therapeutics, Inc. | tm211037d1_ex32.htm |
| EX-31.2 - EX-31.2 - Celldex Therapeutics, Inc. | tm211037d1_ex31x2.htm |
| EX-31.1 - EX-31.1 - Celldex Therapeutics, Inc. | tm211037d1_ex31x1.htm |
| EX-21.1 - EX-21.1 - Celldex Therapeutics, Inc. | tm211037d1_ex21x1.htm |
| 10-K - 10-K - Celldex Therapeutics, Inc. | tm211037-1_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-239463, 333-232253, 333-232255, 333-219867, 333-219869, 333-205694, 333-189336, 333-182142, 333-151728, 333-117602 and 333-151728) and on Form S-3 (Nos. 333-249917, 333-239199, 333-235399 and 333-215747) of Celldex Therapeutics, Inc. of our report dated March 29, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 29, 2021
March 29, 2021